Navigation Links
Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Date:5/25/2010

CALGARY, May 25 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has opened enrollment in its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. The Company had previously received approval from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct the trial in those countries, respectively. Oncolytics intends to conduct the first stage of the trial at approximately 25 centres in the U.S., U.K., and Belgium but may elect to add centres in additional countries.

"Opening enrollment in our first pivotal study in an important step forward in our increasingly late stage REOLYSIN clinical program," said Dr. Brad Thompson, President and CEO of Oncolytics. "We expect enrollment to ramp up over the next quarter as additional centres come on line as the trial progresses."

As previously disclosed, the randomized, two-arm, double-blind, multicentre, two-stage, adaptive Phase 3 trial will assess the intravenous administration of REOLYSIN with the chemotherapy combination of paclitaxel and carboplatin versus the chemotherapy alone in patients with metastatic or recurrent squamous cell carcinoma of the head and neck, or squamous cell cancer of the nasopharynx, who have progressed on or after prior platinum-based chemotherapy. All patients will receive treatment every three weeks (21 day cycles) with paclitaxel and carboplatin and will also receive, on a blinded basis, either intravenous placebo or
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
2. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
3. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
4. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
5. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
6. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
7. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
8. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
9. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
10. Oncolytics Biotech(R) Inc. Announces Unit Offering
11. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 Erlab , the ... since 1968 and Burdinola, supplier of laboratory furniture solutions, ... filtered fume hood. , By integrating ... Burdinola will now offer an innovative solution utilizing the ... of chemicals, best-in-class detection technology, and communication for security ...
(Date:9/23/2014)... 23, 2014 For the fifth time since ... list of the fastest-growing companies. , “We’re so proud ... again by Inc. Magazine,” ExakTime CEO Tony Pappas said. , ... posting a three-year growth rate of 61 percent from 2010 ... by more than 40 percent. , Pappas cited strong performance ...
(Date:9/23/2014)... 23, 2014  Age Defying Dermatology ® , owned ... become one of the first clinics in the Bay ... laser for tattoo removal. The treatment safely and effectively ... years, tattoo removal has been a lengthy, painful, and ... is an opportunity to erase tattoo pigment more efficiently ...
(Date:9/23/2014)... Cambridge Semantics, the leading provider of Smart Data ... the recent ‘Hype Cycle for Life Sciences 2014 ’ ... key insights pertaining to the benefits in the knowledge ... Shanler and Stephen Davies, “The use of these systems ... scientific stakeholders, and support collaboration and innovation strategies as ...
Breaking Biology Technology:Erlab Partners with Burdinola to Deliver an Innovative Filtered Fume Hood 2ExakTime Makes Inc. 5000 List for the Fifth Time 2Age Defy Now Offers World's Most Advanced Technology for Tattoo Removal 2Cambridge Semantics Identified in Gartner’s ‘Hype Cycle for Life Sciences 2014’ Report 2
... Aug. 20 Vical Incorporated,(Nasdaq: VICL ) ... with,the appointment of Andrew R. de Guttadauro as ... Mr. de Guttadauro was Senior Director of,Strategy at ... overseeing the commercial development of that company,s Zevalin,the ...
... with Sales Team Forming and Increased Space, Poised for ... Medical Technologies,Inc., which is developing innovative devices for the ... a VP of Sales, Joseph W.,Rafferty, and has started ... its first product, Pathway PV(TM) Atherectomy System. Recently ...
... and CLAREMONT, Calif., Aug. 14 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products ... the second quarter of 2007 increased more than,35% over ... 139 times,revenues of just $13,351 for the same period ... half of 2007 were $3,256,000 compared to only,$24,374 in ...
Cached Biology Technology:Vical Names Andrew de Guttadauro Vice President, Corporate Development 2Vical Names Andrew de Guttadauro Vice President, Corporate Development 3Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 4Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 5Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 6
(Date:9/22/2014)... ATLANTA September 23, 2014 A new American ... Supplemental Nutrition Assistance Program (SNAP), previously known as ... scores compared with income eligible non-participants. The authors ... programs aimed at enhancing the dietary quality of ... assist low-income individuals and households with the resources ...
(Date:9/22/2014)... Yale University researchers are studying a potential new ... respiratory disease in which scars develop in the lungs ... microRNA mimic, miR-29, which is delivered to lung tissue ... fibrosis, it reversed fibrosis after several days. , ... EMBO Molecular Medicine . , "The mimic, when ...
(Date:9/22/2014)... sequencing technologies continue to evolve rapidly, becoming part of ... appropriate policies and regulatory frameworks to address potential challenges, ... issue of the Journal of Law, Medicine & ... with the Center for Medical Ethics and Health Policy ... tools to jumpstart this process. , Experts with ...
Breaking Biology News(10 mins):Federal food program puts food on the table, but dietary quality could be improved 2Reversing the effects of pulmonary fibrosis 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 3
... an Israeli start-up company, launched its first "solar farm" near ... systems developed by Prof. David Faiman of Ben-Gurion University ... Faiman, who is chairman of the Department of ... for Desert Research, believes the new system will harvest more ...
... for the 61st Annual Meeting of the Rocky Mountain ... 11-13 May 2009 in Orem, Utah. Utah Valley ... library building on the UVU campus. Brigham Young University ... and industry scientists, and graduate and undergraduate students, will ...
... Ill. Researchers at the University of Illinois have ... one or more molecules into the cytoplasm or the ... amounts of cargo, the nanoneedle can also be used ... "Nanoneedle-based delivery is a powerful new tool for studying ...
Cached Biology News:Ben-Gurion University research and technology used in new solar energy farm 2Geoscientists meet to discuss Rocky Mountain geology 2Nanoneedle is small in size, but huge in applications 2
BioGenex IHC Kits for Rodent Tissues are designed for immunohistochemistry on rodent and rabbit tissues that are closely related to the source of the primary antibody. This kit comes with rat seconda...
... is available in a ready-to-use format. ... for dewaxing paraffin-embedded tissue sections prior ... or other analytical methods. The conventional ... dipping the slides in a series ...
... The BioGenex Super ... System is a novel ... proprietary non-biotin polymeric technology. ... high signal to noise ...
... thermal cycler is a compact instrument for gene ... tubes, 12 x 0.5 ml tubes, or a ... a thumbwheel to adjust height and pressure to ... heat pumps provide excellent thermal performance, and the ...
Biology Products: